The Short Course, "Coverage and Reimbursement for Advanced Diagnostics," will be 2-5 pm on Sunday, February 19, in San Francisco. The TriCon conference is a large, international gathering and runs February 19-24.
The short course agenda is here (or below the break). The main conference webpage is here. The course is organized by Katherine Tynan of TynanDX Consulting.
___
http://www.triconference.com/mmtc_content.aspx?id=168859
SUNDAY february 19, 2-5PM
short course #4
COVERAGE AND REIMBURSEMENT
FOR ADVANCED DIAGNOSTICS
Katherine Tynan Ph.D, Tynan Consulting LLC
Girish Putcha, M.D., Ph.D. – Director, Laboratory Science, Palmetto GBA (MolDX)
Kurt Matthes, Vice President, RCM Reengineering and Service, Revenue Cycle Management, TELCOR Inc
Marijke Annis, Commercialization & Reimbursement Strategies, Diagnostics, Ruckus Partners
Bruce Quinn, Bruce Quinn LLC
Girish Putcha, M.D., Ph.D. – Director, Laboratory Science, Palmetto GBA (MolDX)
Kurt Matthes, Vice President, RCM Reengineering and Service, Revenue Cycle Management, TELCOR Inc
Marijke Annis, Commercialization & Reimbursement Strategies, Diagnostics, Ruckus Partners
Bruce Quinn, Bruce Quinn LLC
ABOUT THIS COURSE:
Diagnostic testing has advanced at a rapid rate providing physicians and patients with lifesaving information impacting the course of treatment and care. However from advance to simpler diagnostics the industry faces huge difficulties in securing reimbursement as healthcare in the US transforms itself from an activity based fee for service system, to tying provider reimbursement to improved patient outcomes, savings and quality metrics. In addition high deductible plans and increasing cost transparency are forcing consumers to shop around for cost effective care. Successfully establishing clinical utility with stakeholders both locally and nationally will be a foundational topic of the agenda for this workshop.
- FDA Regulation of Lab Developed tests, impact on pricing and payment
- PAMA and pricing
- Key considerations for the preparation of successful evidence dossiers
- Case examples of favorable and unfavorable HTAs
- Impact of narrowing lab networks and requirements for preauthorization
2:00 Katherine Tynan Ph.D, Tynan Consulting LLC
2:20 Girish Putcha, M.D., Ph.D. – Director, Laboratory Science, Palmetto GBA (MolDX)
2:45 Kurt Matthes, Vice President, RCM Reengineering and Service, Revenue Cycle Management, TELCOR Inc
3:10 Refreshment Break
3:30 Marijke Annis, Commercialization & Reimbursement Strategies, Diagnostics, Ruckus Partners
3:55 Bruce Quinn, Bruce Quinn LLC
4:30 Panel Q&A
5:00 Close of Course